Glucose and lipid metabolism are interconnected in various ways. A key clinical manifestation of this interaction is diabetic dyslipidaemia, which is characterized by high triglycerides, low HDL cholesterol levels, and a predominance of small, dense LDL particles. Over the past decade, our understanding of this interaction has expanded, revealing its complexity. Not only can hypertriglyceridemia and low HDL-C result from disrupted glucose metabolism, but they can also contribute to it. Additionally, it has been established that statins are linked to a modest but significant increase in the risk of developing new-onset diabetes. The exact mechanisms are not entirely understood, but genetic data suggest that lower activity of HMG CoA-reductase, the enzyme targeted by statins, is associated with obesity, higher glucose levels, and diabetes. Interestingly, this increased risk of type 2 diabetes from statin use is not observed in individuals with familial hypercholesterolemia. Moreover, these patients appear to have a lower risk of type 2 diabetes, with higher LDL cholesterol levels correlating with a reduced risk. The potential relationship between lipoprotein and diabetes remains uncertain